Critical Assessments of Computational Hit-finding Experiments Challenge #4: Targeting the Tyrosine Kinase Binding Domain of the E3 Ligase Casitas B-Lineage Lymphoma Proto-Oncogene B, an Immuno-Oncology Target
Abstract The critical assessments of computational hit-finding experiments (CACHE) are prospective benchmarking exercises where small molecule ligands predicted for a nominated protein of interest are procured and tested experimentally. In CACHE #4, 23 participating teams each selected up to 100 compounds designed to bind the E3 ligase CBLB, an immuno-oncology target. The organizers released the first public structure of CBLB in complex with a known ligand at the outset of the challenge to enable the discovery of chemically novel molecules. Out of the 1688 compounds collectively predicted, ten compounds from nine participants showed some sign of activity (primary hits), but only two were convincingly confirmed (validated hits) across multiple biophysical binding assays and in subsequent analogs, and only one of them was chemically novel. The apparent difficulty of finding novel CBLB ligands, previously reflected by the chemical similarity of inhibitors from the patent literature, suggests that potent CBLB hit molecules were either rare in the screened commercial libraries, or that computational methods may have struggled to retrieve presumably present but weak ligands, or that the conformational dynamics of the binding site was not sufficiently accounted for. The successful method was strikingly atypical. Selection from a chemical binding similarity classifier followed by a random forest binding affinity predictor trained on inhibitors from the patent literature was refined using a diffusion-model binding pose predictor. The road to an ML-driven breakthrough in computational hit-finding can take unexpected turns. Which of these turns reveal novel horizons and which are mere distractions will best be investigated and answered collectively. The discovery in CACHE #4 of a novel series of CBLB ligands is not a trivial achievement and may inform medicinal chemistry efforts toward clinical candidates that complement immune checkpoint inhibition to elicit antitumor immune response in cancer patients.
Authors
- Gediminas Gumbis (ORCID: https://orcid.org/0009-0005-4831-8493)
- Keunwan Park (ORCID: https://orcid.org/0000-0002-8783-9495)
- Mykola Protopopov (ORCID: https://orcid.org/0000-0002-2716-4844)
- C.H. Arrowsmith (ORCID: https://orcid.org/0000-0002-4971-3250)
- Yvonne Westermaier (ORCID: https://orcid.org/0000-0002-0462-8650)
- Albina Bolotokova
- Irene Chau (ORCID: https://orcid.org/0000-0002-2313-973X)
- Ryota Ashizawa (ORCID: https://orcid.org/0000-0002-5082-9058)
- Rima Al‐awar (ORCID: https://orcid.org/0000-0002-4185-055X)
- Christoph Gorgulla (ORCID: https://orcid.org/0000-0001-6986-5270)
- Kyle Medley (ORCID: https://orcid.org/0000-0002-9135-0844)
- Jude Wells (ORCID: https://orcid.org/0000-0002-5358-2310)
- David Uehling (ORCID: https://orcid.org/0000-0002-9748-0500)
- Anders Gunnarsson (ORCID: https://orcid.org/0000-0002-6334-9520)
- David J. Bearss (ORCID: https://orcid.org/0000-0003-4940-9942)
- Kristina Edfeldt (ORCID: https://orcid.org/0000-0002-0550-1133)
- Abd Al‐Aziz A. Abu‐Saleh (ORCID: https://orcid.org/0000-0002-3546-5161)
- Douglas R. Houston (ORCID: https://orcid.org/0000-0002-3469-1546)
- Miles McGibbon (ORCID: https://orcid.org/0000-0001-8277-3178)
- Elisa Gibson (ORCID: https://orcid.org/0000-0002-7112-337X)
- Oleksii Hrabovskyi
- Kevin P. Bishop (ORCID: https://orcid.org/0000-0002-8357-854X)
- Uta F. Lessel (ORCID: https://orcid.org/0000-0002-1698-6017)
- Olga O. Tarkhanova (ORCID: https://orcid.org/0000-0003-1880-2872)
- Conrad Veranso Simoben (ORCID: https://orcid.org/0000-0002-5958-6961)
- Vera Pütter (ORCID: https://orcid.org/0000-0001-9065-1322)
- Sergei Kotelnikov (ORCID: https://orcid.org/0000-0001-9400-101X)
- Dima Kozakov (ORCID: https://orcid.org/0000-0003-0464-4500)
- Wim Dehaen (ORCID: https://orcid.org/0000-0002-9597-0629)
- James Wellnitz (ORCID: https://orcid.org/0000-0002-9181-3431)
- Tudor Ionel Oprea (ORCID: https://orcid.org/0000-0002-6195-6976)
- Hugo J. Bohórquez (ORCID: https://orcid.org/0000-0001-6130-4233)
- Wei Lu (ORCID: https://orcid.org/0000-0002-1572-2909)
- Boyang Ni (ORCID: https://orcid.org/0009-0008-0483-8886)
- Diane Joseph‐McCarthy (ORCID: https://orcid.org/0000-0001-9685-6177)
- Sandro Cosconati (ORCID: https://orcid.org/0000-0002-8900-0968)
- J C Zhang (ORCID: https://orcid.org/0000-0001-7844-6035)
- Brooks Paige (ORCID: https://orcid.org/0000-0002-4797-1563)
- Shuangjia Zheng (ORCID: https://orcid.org/0000-0001-9747-4285)
- Matthieu Schapira (ORCID: https://orcid.org/0000-0002-1047-3309)
- Lars Wortmann (ORCID: https://orcid.org/0000-0001-6514-947X)
- Eva Nittinger (ORCID: https://orcid.org/0000-0001-7231-7996)
- Alexander Tropsha (ORCID: https://orcid.org/0000-0003-3802-8896)
- Edina Rosta (ORCID: https://orcid.org/0000-0002-9823-4766)
- Christopher Secker (ORCID: https://orcid.org/0000-0002-7222-536X)
- Hariprasad Vankayalapati (ORCID: https://orcid.org/0000-0002-5477-2124)
- Charuvaka Muvva (ORCID: https://orcid.org/0000-0001-5521-213X)
- Suzanne Z. Ackloo (ORCID: https://orcid.org/0000-0002-9696-1839)
- Michele Roggia (ORCID: https://orcid.org/0009-0009-3860-2502)
- Benito Natale (ORCID: https://orcid.org/0009-0002-2065-2535)
- Lin Chen (ORCID: https://orcid.org/0000-0002-8480-6559)
- Yuchen Zhou (ORCID: https://orcid.org/0009-0007-6216-9708)
- Madhushika Silva (ORCID: https://orcid.org/0009-0001-7060-0445)
- Laurent Hoffer (ORCID: https://orcid.org/0000-0003-1906-7128)
- Duanhua Cao (ORCID: https://orcid.org/0009-0006-0140-7998)
- Oleksandra Herasymenko (ORCID: https://orcid.org/0000-0002-1176-1476)
- Andrea Karlova (ORCID: https://orcid.org/0009-0001-5660-5952)
- Dakota Treleaven (ORCID: https://orcid.org/0009-0006-6458-0042)
- Olha Semenenko (ORCID: https://orcid.org/0000-0001-7575-0429)
- Sara Ziadat (ORCID: https://orcid.org/0009-0000-4177-3104)
- Levon Halabelian
- Runze Zhang
- John J. Irwin
- Yurii Moroz
- Konstantin Popov
- Gennady Poda
- Yogesh Sabnis
- Vincent Blay
- Beck Hartmut
- Anders Hogner
- Peter Loppnau
- Mingyue Zheng
- Rachel J. Harding (ORCID: https://orcid.org/0000-0002-1134-391X)
- Jie Yu
Institutions
- AstraZeneca (United Kingdom) (GB)
- Boston University (US)
- Ontario Institute for Cancer Research (CA)
- University of North Carolina at Chapel Hill (US)
- St. Jude Children's Research Hospital (US)
- University Health Network (CA)
- Boehringer Ingelheim (Germany) (DE)
- Karolinska University Hospital (SE)
- Harvard University (US)
- University of California, San Francisco (US)
- University of California, Santa Cruz (US)
- University of Toronto (CA)
- Taras Shevchenko National University of Kyiv (UA)
- Zuse Institute Berlin (DE)
- University of Campania "Luigi Vanvitelli" (IT)
- Chinese Academy of Sciences (CN)
- Princess Margaret Cancer Centre (CA)
- Structural Genomics Consortium (CA)
- Karolinska Institutet (SE)
- Boehringer Ingelheim (Austria) (AT)
- Korean Association Of Science and Technology Studies (KR)
- Palladin Institute of Biochemistry (UA)
- BioNTech (United States) (US)
- University College London (GB)
- Enamine (Ukraine) (UA)
- Korea Institute of Science and Technology (KR)
- Massachusetts Institute of Technology (US)
- Bayer (Germany) (DE)
- The University of Texas at Austin (US)
- University of Chemistry and Technology, Prague (CZ)
- University of Edinburgh (GB)
Publication Details
- Journal
- Journal of Chemical Information and Modeling
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1021/acs.jcim.6c02396
- Primary Topic
- Computational Drug Discovery Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bill and Melinda Gates Foundation
- Amgen
- Bristol-Myers Squibb
- McGill University
- Diamond Light Source
- European Federation of Pharmaceutical Industries and Associations
- Innovative Health Initiative
- European Commission
- Deutsche Forschungsgemeinschaft
- Ministry of Oceans and Fisheries
- Korea Institute of Science and Technology
- National Research Foundation of Korea
- Hospital for Sick Children
- Innovative Medicines Initiative
- Korea Institute of Marine Science and Technology promotion
- Ministry of Science and ICT, South Korea
- Alliance de recherche numérique du Canada
- HORIZON EUROPE Framework Programme
- Canadian Institutes of Health Research
- Compute Ontario